文献速递生殖医学产科

胚胎活检与单胎妊娠围产结局:16246例冻胚移植周期分析

Embryo biopsy and perinatal outcomes of singleton pregnancies: an analysis of 16,246 frozen embryo transfer cycles reported in the Society for Assisted Reproductive Technology Clinical Outcomes Reporting System.
PubMed 文献 · Am J Obstet Gynecol · 2020-10-28

该回顾性研究基于SART CORS 2014-2015年数据,比较了经胚胎活检(PGT)与未活检的单囊胚冻胚移植后单胎妊娠的围产结局。多因素回归校正混杂因素后,PGT组早产 odds 显著升高(aOR 1.20,95%CI 1.09-1.33),出生体重、SGA、LGA及巨大儿风险无显著差异。

要点

  • PGT组早产风险较未活检组升高20%(aOR 1.20,95%CI 1.09-1.33)。
  • 校正后出生体重、SGA、LGA及巨大儿风险均无显著差异。
  • PGT组母亲平均年龄更高(35.8±4.1 vs 33.7±3.9岁)。

核心结论

  • 与未行PGT的冻胚移植相比,PGT冻胚移植与早产可能性小幅增加相关(aOR 1.20,95%CI 1.09-1.33)。
  • 早产风险增加幅度虽小,但仍需进一步研究验证。

研究设计与样本

  • 回顾性分析SART CORS中2014-2015年启动的自体冻胚移植周期,限单囊胚移植后单胎活产。
  • 共纳入16246个周期,其中6244例移植经PGT的囊胚,10002例移植未活检囊胚。
  • 采用多因素线性回归分析出生体重和Z-score,逻辑回归分析二分类结局,并校正错误发现率。

主要发现

  • PGT组母亲平均年龄(35.8±4.1 vs 33.7±3.9岁;P<.001)及既往自然流产比例(37.3% vs 27.7%;P<.001)均高于非PGT组。
  • 双变量分析显示PGT组SGA发生率更高(4.8% vs 4.0%;P=.008),早产率更高(14.1% vs 12.5%;P=.005),LGA(16.3% vs 18.2%;P=.003)和巨大儿(11.1% vs 12.4%;P=.013)发生率更低。
  • 多因素校正后,PGT组早产 odds 显著升高(aOR 1.20;95%CI 1.09-1.33;P<.001)。
  • 多因素校正后,出生体重(-14.63;95%CI -29.65至0.38;P=.056)、出生体重Z-score(-0.03;95%CI -0.06至0.00;P=.081)、SGA(aOR 1.17;95%CI 0.99-1.38;P=.066)、LGA(aOR 0.96;95%CI 0.88-1.06;P=.418)及巨大儿(aOR 0.96;95%CI 0.85-1.07;P=.427)均无显著差异。
  • 在有明确不孕诊断的亚组(n=14285)中结果一致。

关键数值与推荐

  • 早产:PGT组aOR 1.20(95%CI 1.09-1.33;P<.001)。
  • 出生体重:β=-14.63(95%CI -29.65至0.38;P=.056)。
  • 出生体重Z-score:β=-0.03(95%CI -0.06至0.00;P=.081)。
  • SGA:aOR 1.17(95%CI 0.99-1.38;P=.066)。
  • LGA:aOR 0.96(95%CI 0.88-1.06;P=.418);巨大儿:aOR 0.96(95%CI 0.85-1.07;P=.427)。

临床怎么用

  • 对行PGT后冻胚移植的单胎妊娠,应关注早产风险并加强产前监测。
  • 咨询时可告知PGT后早产风险小幅增加,但出生体重及巨大儿风险未见显著差异。

局限性

  • 本研究为回顾性分析,可能存在未校正的混杂因素。
  • 仅纳入2014-2015年SART CORS数据,结论外推需谨慎。
  • 早产风险增加幅度较小,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preimplantation genetic testing is commonly performed by removing cells from the trophectoderm, the outer layer of the blastocyst, which subsequently forms the placenta. Because preimplantation genetic testing removes the cells that are destined to form the placenta, it is possible that preimplantation genetic testing could be associated with an increased risk for adverse outcomes associated with abnormal placentation. Despite the increasing utilization of preimplantation genetic testing, few studies have investigated the perinatal outcomes, with published studies yielding contradictory findings and using small sample sizes. OBJECTIVE: This study aimed to compare the perinatal outcomes of singleton pregnancies conceived following frozen embryo transfer of a single, autologous blastocyst either with or without preimplantation genetic testing. STUDY DESIGN: This was a retrospective analysis of autologous frozen embryo transfer cycles that led to singleton live births per the Society for Assisted Reproductive Technology Clinical Outcomes Reporting System, including cycles initiated between 2014 and 2015. The perinatal outcomes, including birthweight, Z-score, small for gestational age, large for gestational age, macrosomia, and preterm birth, were compared between pregnancies with or without preimplantation genetic testing. We conducted multivariable linear regression analyses for the birthweight and Z-score and logistic regression for the binary outcomes. A false discovery rate was adjusted to decrease the type I error from multiple hypothesis testing. RESULTS: Of the 16,246 frozen embryo transfers resulting in singleton births included in this analysis, 6244 involved the transfer of a single blastocyst that had undergone preimplantation genetic testing, and the remainder (n=10,002) involved the transfer of a single blastocyst that had not undergone a biopsy. When compared with the women from the nonpreimplantation genetic testing group, the average maternal age (35.8±4.1 vs 33.7±3.9; P<.001) and prevalence of prior spontaneous abortion (37.3% vs 27.7%; P<.001) were higher among women from the preimplantation genetic testing group. Bivariate analysis revealed a higher prevalence of small-for-gestational-age newborns (4.8% vs 4.0%; P=.008) and premature delivery (14.1% vs 12.5%; P=.005) and a lower prevalence of large-for-gestational-age newborns (16.3% vs 18.2%; P=.003) and macrosomia (11.1% vs 12.4%; P=.013) among the preimplantation genetic testing pregnancies. Multivariate regression analyses, adjusting for the year of transfer, maternal age, maternal body mass index, smoking status (3 months before the treatment cycle), obstetrical histories (full-term birth, preterm birth, and spontaneous abortion), infertility diagnosis, and infant sex suggested a significantly increased odds of preterm birth (adjusted odds ratio, 1.20; 95% confidence interval, 1.09-1.33; P<.001) from preimplantation genetic testing blastocysts. Birthweight (-14.63; 95% confidence interval, -29.65 to 0.38; P=.056), birthweight Z-score (-0.03; 95% confidence interval, -0.06 to 0.00; P=.081), and odds of small-for-gestational-age newborns (adjusted odds ratio, 1.17; 95% confidence interval, 0.99-1.38; P=.066), large-for-gestational-age newborns (adjusted odds ratio, 0.96; 95% confidence interval, 0.88-1.06; P=.418), and macrosomia (adjusted odds ratio, 0.96; 95% confidence interval, 0.85-1.07; P=.427) did not differ between the frozen transfer cycles with or without preimplantation genetic testing in the analysis adjusted for the confounders. Subgroup analysis of the cycles with a stated infertility diagnosis (n=14,285) yielded consistent results. CONCLUSION: Compared with frozen embryo transfer cycles without preimplantation genetic testing, the frozen embryo transfer cycles with preimplantation genetic testing was associated with a small increase in the likelihood of preterm birth. Although the increase in the risk for prematurity was modest in magnitude, further investigation is warranted.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Li M, Kort J, Baker VL, et al. Embryo biopsy and perinatal outcomes of singleton pregnancies: an analysis of 16,246 frozen embryo transfer cycles reported in the Society for Assisted Reproductive Technology Clinical Outcomes Reporting System. Am J Obstet Gynecol. 2020. PMID: 33129765. doi:10.1016/j.ajog.2020.10.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。